Categories: BioTechDevelopmentDrugFamilyHuman
Kindred Biosciences is a veterinary biopharmaceutical company focused on saving and improving the lives of cats, dogs, and horses. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for animal companions. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
Location: United States, California, Burlingame
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.10.2019 | - | $50M | - |
Mentions in press and media 16
| Date | Title | Description | Source |
| 08.03.2024 | DEADLINE ALERT for PANW, PLCE, SNOW, and KIND: The Law Offic... | - | globenewsw... |
| 17.06.2021 | The return of former Athenahealth CEO, Jonathan Bush | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 17.06.2021 | The return of former Athenahealth CEO, Jonathan Bush | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 16.06.2021 | Elanco Announces Agreement to Acquire Kindred Biosciences | | prnewswire... |
| 02.06.2021 | Kindred Biosciences Announces Positive Results from Pivotal ... | | prnewswire... |
| 11.05.2021 | Kindred Biosciences Announces First Quarter 2021 Financial R... | | prnewswire... |
| 11.05.2021 | KINDRED BIOSCIENCES, INC.
Kindred Biosciences : Announces F... | SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceut... | marketscre... |
| 28.04.2021 | ELANCO ANIMAL HEALTH INCORPORATED
Elanco Animal Health Inco... | SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmace... | marketscre... |
| 28.04.2021 | Kindred Biosciences Announces Acceptance of Parvovirus Antib... | | prnewswire... |
| 16.03.2021 | Kindred Biosciences Announces Fourth Quarter and Full Year 2... | | prnewswire... |
| 25.02.2021 | Kindred Biosciences Announces Submission of Parvovirus Monoc... | | prnewswire... |
| 09.02.2021 | Kindred Biosciences Announces Two New Appointments to Board ... | | prnewswire... |
| 21.12.2020 | Kindred Biosciences Announces Positive Results from Pilot Fi... | | prnewswire... |
| 11.12.2020 | Kindred Biosciences Announces Agreement Granting Elanco Excl... | | prnewswire... |
| 09.11.2020 | Kindred Biosciences Announces Third Quarter 2020 Financial R... | | prnewswire... |
| 02.10.2019 | Kindred Biosciences Secures $50M Debt Facility From Solar Ca... | Kindred Biosciences, Inc. (Nasdaq: KIN), a San Francisco, CA-based commercial-stage biopharmaceutica... | finsmes.co... |
Show more
Reviews 0
